Bladder Cancer | Tumor

How One Organization is Honoring Bladder Cancer Awareness Month During the COVID-19 Pandemic

May 14th 2020

Amid the COVID-19 pandemic, the Bladder Cancer Advocacy Network is honoring Bladder Cancer Awareness Month in a slightly different way from previous years.

Bladder Cancer

May 6th 2020

Understanding bladder cancer.

FDA's Jelmyto Approval Offers Patients 'Very Sorely Needed' Treatment Option

April 22nd 2020

The Food and Drug Administration’s approval of Jelmyto (mitomycin gel]) in low-grade upper tract urothelial cancer offers patients a much-needed treatment option, according to one expert.

Padcev and Keytruda Combination Shows Promise for More Urothelial Carcinoma Options

April 17th 2020

Data from the phase 1b/2 trial of Padcev in combination with Keytruda displayed promise for patients with metastatic urothelial carcinoma, but further research is needed.

FDA Approves First Low-Grade Upper Tract Urothelial Cancer Therapy

April 15th 2020

The Food and Drug Administration approved Jelmyto to treat patients with low-grade upper tract urothelial cancer.

Looking Toward Combination Therapies in Metastatic Bladder Cancer

April 14th 2020

Immunotherapy and targeted therapy medications have brought new hope to patients with advanced disease.

Immunotherapy After Chemotherapy Improves Outcomes in Metastatic Bladder Cancer

April 10th 2020

Using immunotherapy earlier, immediately after the conclusion of chemotherapy to treat metastatic bladder cancer, can delay the time until disease progression.

Electronic Cigarette Use and Risk of Bladder Cancer

April 2nd 2020

A new study links e-cigarette use to bladder cancer but experts say more research is needed.

Experts Call for Refined Treatment Paradigm in Urothelial Cancer

March 17th 2020

There are a number of treatment options available for patients with urothelial cancer, however, experts want to refine the current treatment paradigm amid new drugs entering the landscape.

The Future of Immunotherapy in Bladder Cancer

February 23rd 2020

Treatment for patients with bladder cancer is moving away from VEGF-targeted therapies toward immune checkpoint inhibition, according to one expert.

Padcev, Keytruda Combination Proves Impactful for Patients with Metastatic Urothelial Cancer

February 20th 2020

The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.

Padcev Combination Shows Promise in Patients with Metastatic Bladder Cancer

February 16th 2020

The combination of Padcev plus Keytruda induced a high rate of durable objective response rates in patients with locally advanced or metastatic urothelial cancer.

New Blood Test May Detect Cancer Cells in Asymptomatic Patients

February 5th 2020

A new study supported the use of a blood test to detect clusters of cancer cells in the blood of asymptomatic individuals, meaning, patients could have a non-invasive screening and testing method.

Testing Combinations in Metastatic Urothelial Cancer

January 29th 2020

Better response rates may be seen in patients with advanced bladder cancer when two therapies are combined.

2020 Bladder Cancer Research Innovation Award

January 16th 2020

The Bladder Cancer Advocacy Network announces it's Bladder Cancer Research Innovation Award.

FDA Grants Accelerated Approval to Astellas

January 14th 2020

FDA has given an accelerated approval to Padcev in the treatment of patients with locally advanced or metastatic urothelial cancer.

Announcing BCAN 2020 Young Investigator Awards

January 11th 2020

The Bladder Cancer Advocacy Network (BCAN) is pleased to announce two 2020 Young Investigator Awards (YIA), to support the development of outstanding early-career research scientists and clinical cancer research investigators.

What You Need to Know About the FDA's Approval of Keytruda in High-Risk NMBIC

January 11th 2020

This new option may save patients with high-risk non-muscle invasive bladder cancer from having to undergo a radical cystectomy to treat their disease.

Bladder Cancer Advocacy Network Turns 15

January 10th 2020

At 15 years old the Bladder Cancer Advocacy Network looks back and takes a look ahead.

FDA Approves Keytruda for High-Risk, Non-Muscle Invasive Bladder Cancer

January 9th 2020

The Food and Drug Administration approved Keytruda for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer.

Phase 3 Interim Analysis Shows Improved Survival in Patients with Bladder Cancer

January 7th 2020

Patients with previously untreated locally advanced or metastatic urothelial carcinoma treated with Bavencio and best supportive care as a first-line maintenance therapy experienced significantly longer survival.

What You Need to Know About the FDA's Approval of Padcev to Treat Bladder Cancer

December 28th 2019

The Food and Drug Administration’s accelerated approval of Padcev offers patients with advanced bladder cancer a potential standard of care.

I Dodged a Bullet

December 26th 2019

FDA Approves Padcev to Treat Bladder Cancer

December 19th 2019

The Food and Drug Administration approved Padcev for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.

FDA Grants Priority Review to Keytruda for Non-Muscle Invasive Bladder Cancer

December 3rd 2019

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Keytruda (pembrolizumab), an anti-PD-1 immunotherapy, for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC), according to Merck, the drug’s manufacturer.

First-Line Tecentriq Plus Chemo Shows Promise in Metastatic Bladder Cancer

October 10th 2019

The IMvigor130 trial showed chemotherapy plus immunotherapy in patients with metastatic urothelial cancer could prolong the time to disease progression.

Newly Approved Targeted Therapy Paves the Way for Patients With Advanced Bladder Cancer

September 14th 2019

The oral medication Balversa (erdafitinib) shows promise in patients who have FGFR3 gene alterations.

CURE's Top 5 Stories: July 2019

August 1st 2019

Here are the top 5 CURE stories for July 2019.

Rapid Autopsy Offers New Insights into Advanced Bladder Cancer Research and Treatment

July 22nd 2019

Genomic distinctions between bladder cancer variances are revealed through rapid autopsy, according to one study, and may help push forward bladder cancer research.

How One Patient Turned Caregiver Leaves No Stone Unturned

July 18th 2019

Karen, who received her bladder cancer diagnosis in 2010, was faced with a similar challenge after her husband was diagnosed with the same disease just six years later.